Ranked by the Match Score
Luci scores 62 on our six-factor Match Score (ranked #301 of 537). Here are the providers we'd weigh against it, ranked by that same honest model. Or take the quiz for your personalized match.
The widest compounded menu in the ranking at a rock-bottom GLP-1 entry — microdosed semaglutide from ~$49/mo, tirzepatide from ~$99/mo, plus oral GLP-1, intranasal NAD+, recovery peptides and bioidentical HRT, all LegitScript-certified and HIPAA-compliant.
Low double-digit sema pricing, an oral option, and all-50-state reach — a strong value pick for the needle-averse.
The best all-around match: nationwide access, both molecules at one flat, no-surprise price, and an easy exit.
The only program here carrying both LegitScript and ACHC accreditation, with an oral lozenge route on both molecules at the cheapest entry in this ranking.
Regulatory notice
FDA issued Strut Health, LLC dba Strut a warning letter in February 2026. You can read it in FDA's warning-letter database. We still list Strut Health, and we may earn a commission if you start care through the link on this page.
The deepest menu here — injection, oral and two microdose lines — with the amount billed today published at every rung, and a membership fee that lives only in the Terms.
Among the cheapest month-to-month pairings on either molecule, and genuinely flat by dose — provided you get past the tab the pricing block opens on.
The highest Transparency score here, and it is not close: twenty-four prices on one public page and four dispensing pharmacies named with street addresses.
A men's-health-focused program with strong coaching, available across 20 states.
Answer six quick questions and we'll reweight the Match Score to your budget, format, timing, coverage and support — then rank every provider for you.
Take the quizPricing, states and verification reflect each provider's public disclosures at last review; the Match Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.